Alternative administration routes and delivery technologies for polio vaccines

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Expert Review of Vaccines

• Publication date

  2016-03-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14760584.2016.1158650PMID 26912100
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• From Pakistan a line of hope for ‘The Polio Eradication and Endgame Strategic Plan 2013–2018’

  2016cited by this paper
• Vaccines against enteric infections for the developing world

  2015cited by this paper
• Inactivated polio vaccination using a microneedle patch is immunogenic in the rhesus macaque.

  2015cited by this paper
• Alternative delivery of a thermostable inactivated polio vaccine.

  2015cited by this paper
• Immune responses after fractional doses of inactivated poliovirus vaccine using newly developed intradermal jet injectors: a randomized controlled trial in Cuba.

  2015influential reference
• The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.

  2015cited by this paper
• Polio endgame: the global introduction of inactivated polio vaccine

  2015cited by this paper
• Layer-by-Layer Assembly of Inactivated Poliovirus and N-Trimethyl Chitosan on pH-Sensitive Microneedles for Dermal Vaccination.

  2015cited by this paper
• A microneedle patch containing measles vaccine is immunogenic in non-human primates.

  2015cited by this paper
• Intradermal inactivated poliovirus vaccine: a preclinical dose-finding study.

  2015cited by this paper
• Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial.

  2015cited by this paper
• Affordable inactivated poliovirus vaccine: strategies and progress.

  2014cited by this paper
• Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system

  2014cited by this paper
• Buccal and sublingual vaccine delivery

  2014cited by this paper
• Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial.

  2014cited by this paper
• Efficacy of inactivated poliovirus vaccine in India

  2014cited by this paper
• Novel Hollow Microneedle Technology for Depth-Controlled Microinjection-Mediated Dermal Vaccination: A Study with Polio Vaccine in Rats

  2014cited by this paper
• Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01

  2014influential reference
• Enzyme-linked immunospot assays for direct ex vivo measurement of vaccine-induced human humoral immune responses in blood

  2013cited by this paper
• Priming after a fractional dose of inactivated poliovirus vaccine.

  2013cited by this paper
• Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults.

  2013influential reference
• Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues.

  2012cited by this paper
• Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge

  2012cited by this paper
• Mucosal vaccine design and delivery.

  2012cited by this paper
• Intradermal fractional dose inactivated polio vaccine: a review of the literature.

  2012cited by this paper
• Immunogenicity of supplemental doses of poliovirus vaccine for children aged 6-9 months in Moradabad, India: a community-based, randomised controlled trial.

  2012cited by this paper
• The final phase of polio eradication: new vaccines and complex choices.

  2012cited by this paper
• Vaccines against mucosal infections.

  2012cited by this paper
• Randomized controlled study of fractional doses of inactivated poliovirus vaccine administered intradermally with a needle in the Philippines.

  2012cited by this paper
• Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa.

  2012cited by this paper
• Towards tailored vaccine delivery: needs, challenges and perspectives.

  2012cited by this paper
• Microneedle technologies for (trans)dermal drug and vaccine delivery.

  2012cited by this paper
• Intradermal delivery of vaccines: potential benefits and current challenges.

  2011cited by this paper
• Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba.

  2010cited by this paper
• Effectiveness of Immunization against Paralytic Poliomyelitis in Nigeria

  2010cited by this paper
• Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.

  2010cited by this paper
• Polio vaccines and polio immunization in the pre-eradication era: WHO position paper--recommendations.

  2010cited by this paper
• Polio vaccines and polio immunization in the pre-eradication era: WHO position paper.

  2010cited by this paper
• Fractional doses of inactivated poliovirus vaccine in Oman.

  2010influential reference
• Intradermal vaccine delivery: will new delivery systems transform vaccine administration?

  2008cited by this paper
• Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice

  2008cited by this paper
• Monovalent type 1 oral poliovirus vaccine in newborns.

  2008cited by this paper
• In vivo assessment of safety of microneedle arrays in human skin.

  2008cited by this paper
• Effectiveness of immunization against paralytic poliomyelitis in Nigeria.

  2008cited by this paper
• Preventing contamination between injections with multiple-use nozzle needle-free injectors: a safety trial.

  2008cited by this paper
• Serologic response to inactivated poliovirus vaccine: a randomized clinical trial comparing 2 vaccination schedules in Puerto Rico.

  2007cited by this paper
• Modulation of Poliovirus Replicative Fitness in HeLa Cells by Deoptimization of Synonymous Codon Usage in the Capsid Region

  2006cited by this paper
• Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population

  2006cited by this paper
• Rational Design of Genetically Stable, Live-Attenuated Poliovirus Vaccines of All Three Serotypes: Relevance to Poliomyelitis Eradication

  2006cited by this paper
• Transcutaneous immunization with inactivated influenza virus induces protective immune responses.

  2006cited by this paper
• Buccal bioadhesive drug delivery--a promising option for orally less efficient drugs.

  2006cited by this paper
• NALT- versus PEYER'S-patch-mediated mucosal immunity

  2004cited by this paper
• Pluronic F127-based systemic vaccine delivery systems.

  2004cited by this paper
• Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland.

  2004cited by this paper
• Optimization of an Alum-Adsorbed Vaccine Powder Formulation for Epidermal Powder Immunization

  2003cited by this paper
• Epidermal powder immunization of mice and monkeys with an influenza vaccine.

  2003cited by this paper
• Epidermal powder immunization using non-toxic bacterial enterotoxin adjuvants with influenza vaccine augments protective immunity.

  2002cited by this paper
• Age‐ and dose‐interval‐dependent antibody responses to inactivated poliovirus vaccine

  2001cited by this paper
• A model to assess the infection potential of jet injectors used in mass immunisation.

  2001cited by this paper
• Mucosal immunity and tolerance: relevance to vaccine development

  1999cited by this paper
• Immune response of infants to fractional doses of intradermally administered inactivated poliovirus vaccine.

  1998cited by this paper
• Drug delivery matrix containing native protein precipitates suspended in a poloxamer gel.

  1997cited by this paper
• Identification of an immunodominant T cell epitope on cholera toxin

  1996cited by this paper
• Defining Surrogate Serologic Tests with Respect to Predicting Protective Vaccine Efficacy: Poliovirus Vaccination

  1995cited by this paper
• Immune response of infants to inactivated poliovirus vaccine injected intradermally.

  1992cited by this paper
• Immune response to intradermally injected inactivated poliovirus vaccine.

  1991cited by this paper
• Persistence of poliovirus-neutralizing antibodies 2–16 years after immunization with live attenuated vaccine. A seroepidemiologic survey in the mainland of Venice.

  1988cited by this paper
• Mucosal immune response to poliovirus vaccines in childhood.

  1984cited by this paper
• [Preparation and use of inactivated vaccine against acute anterior poliomyelitis in the Netherlands].

  1979cited by this paper
• Antibody persistence after primary immunization with trivalent oral poliovirus vaccine.

  1977cited by this paper
• Immunoglobulin response in serum and secretions after immunization with live and inactivated poliovaccine and natural infection.

  1968cited by this paper
• Response to poliomyelitis vaccination.

  1958cited by this paper
• Antibody response following intradermal or oral administration of formalinised poliomyelitis.

  1958cited by this paper
• Antibody response to poliomyelitis vaccine administered by jet injection.

  1958cited by this paper
• Polio vaccination in Denmark in April-June 1955. I. The production of formalinized poliovaccine and preliminary results.

  1955cited by this paper
• Large-scale administration of vaccines by means of an automatic jet injection syringe.

  1955cited by this paper
• Recent studies on immunization against poliomyelitis.

  1953cited by this paper

• Facilitating the use of the target product profile in academic research: a systematic review

  2024cites this paper
• Current and next-generation formulation strategies for inactivated polio vaccines to lower costs, increase coverage, and facilitate polio eradication

  2022cites this paper
• Immunogenicity and safety of sabin-strain based inactivated poliovirus vaccine replacing salk-strain based inactivated poliovirus vaccine: An innovative application of different strain-IPVs replacement.

  2021cites this paper
• Skin delivery of trivalent Sabin inactivated poliovirus vaccine using dissolvable microneedle patches induces neutralizing antibodies.

  2019cites this paper
• Engineering a Rugged Nanoscaffold To Enhance Plug-and-Display Vaccination

  2018cites this paper
• The effect of formulation on spray dried Sabin inactivated polio vaccine

  2018cites this paper
• Immunogenicity of sequential inactivated and oral poliovirus vaccines (OPV) versus inactivated poliovirus vaccine (IPV) alone in healthy infants: A systematic review and meta-analysis

  2018cites this paper
• Drying Made Easy : Spray drying a promising technology for the production of stable vaccine and therapeutic protein formulations

  2018cites this paper
• Developments in the formulation and delivery of spray dried vaccines

  2017cites this paper
• Intranasal and sublingual delivery of inactivated polio vaccine.

  2017cites this paper
• Vial usage, device dead space, vaccine wastage, and dose accuracy of intradermal delivery devices for inactivated poliovirus vaccine (IPV)

  2017cites this paper